Corcept Therapeutics Announces Third Quarter 2015 Results and Provides Corporate Update
November 05, 2015 16:05 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwired - Nov 5, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT)
GAAP net loss in the third quarter narrows to $0.6 million, from $6.0...
Corcept Therapeutics to Announce Third Quarter Financial Results and Corporate Update and Host Conference Call
October 29, 2015 16:05 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwired - Oct 29, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on...
Results of Phase 1 Trial of Next-Generation Cortisol Modulator CORT125134 to Be Presented at Annual Meeting of the American Association of Pharmaceutical Scientists
October 13, 2015 16:05 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwired - Oct 13, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for...
Corcept Therapeutics Appoints Robert S. Fishman, M.D., as Chief Medical Officer
September 28, 2015 08:30 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwired - Sep 28, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for...
Corcept Therapeutics Announces Second Quarter 2015 Results and Provides Corporate Update
August 05, 2015 16:05 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwired - Aug 5, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT)
Per-share net loss in the second quarter narrows to $0.02, from...
Corcept Therapeutics to Announce Second Quarter Financial Results and Corporate Update and Host Conference Call
July 29, 2015 16:05 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwired - Jul 29, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on...
Corcept Therapeutics Appoints Daniel Swisher to Board of Directors
June 22, 2015 08:30 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwired - Jun 22, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs...
Corcept Therapeutics Announces Poster Presentations on Mifepristone for the Treatment of Patients With Cushing's Syndrome at the 27th Annual American Association of Clinical Endocrinologists
May 14, 2015 16:05 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwired - May 14, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for...
Corcept Therapeutics' Mifepristone Combined With Eribulin to Improve Antitumor Activity in Patients With Triple-Negative Breast Cancer
May 13, 2015 19:30 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwired - May 13, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that...
Corcept Therapeutics Announces First Quarter 2015 Results and Provides Corporate Update
May 07, 2015 16:05 ET
|
Corcept Therapeutics
MENLO PARK, CA--(Marketwired - May 7, 2015) - Corcept Therapeutics Incorporated (NASDAQ: CORT)
Per-share net loss in first quarter narrows to $0.05, from $0.14 in the...